| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 682 | 2019 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 349 | 2019 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 308 | 2021 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 243 | 2019 |
| The third group of the B7‐CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3 M Janakiram, UA Shah, W Liu, A Zhao, MP Schoenberg, X Zang Immunological reviews 276 (1), 26-39, 2017 | 223 | 2017 |
| New immunotherapies targeting the PD-1 pathway JM Chinai, M Janakiram, F Chen, W Chen, M Kaplan, X Zang Trends in pharmacological sciences 36 (9), 587-595, 2015 | 219 | 2015 |
| Rapid progression of adult T-cell leukemia–lymphoma after PD-1 inhibitor therapy L Ratner, TA Waldmann, M Janakiram, JE Brammer New England Journal of Medicine 378 (20), 1947-1948, 2018 | 214 | 2018 |
| Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein M Janakiram, JM Chinai, S Fineberg, A Fiser, C Montagna, ... Clinical cancer research 21 (10), 2359-2366, 2015 | 153 | 2015 |
| HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families M Janakiram, JM Chinai, A Zhao, JA Sparano, X Zang Oncoimmunology 4 (8), e1026534, 2015 | 111 | 2015 |
| HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status H Cheng, M Janakiram, A Borczuk, J Lin, W Qiu, H Liu, JM Chinai, ... Clinical Cancer Research 23 (3), 825-832, 2017 | 107 | 2017 |
| Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade DA Rauch, KC Conlon, M Janakiram, JE Brammer, JC Harding, BH Ye, ... Blood, The Journal of the American Society of Hematology 134 (17), 1406-1414, 2019 | 95 | 2019 |
| Structure and cancer immunotherapy of the B7 family member B7x H Jeon, V Vigdorovich, SC Garrett-Thomson, M Janakiram, ... Cell reports 9 (3), 1089-1098, 2014 | 80 | 2014 |
| Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies M Janakiram, V Pareek, H Cheng, DM Narasimhulu, X Zang Immunotherapy 8 (7), 809-819, 2016 | 77 | 2016 |
| Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1–negative human lung cancers H Cheng, A Borczuk, M Janakiram, X Ren, J Lin, A Assal, B Halmos, ... Clinical Cancer Research 24 (8), 1954-1964, 2018 | 76 | 2018 |
| Chimeric antigen receptor T cell therapy during the COVID-19 pandemic V Bachanova, MR Bishop, P Dahi, B Dholaria, SA Grupp, B Hayes-Lattin, ... Biology of Blood and Marrow Transplantation 26 (7), 1239-1246, 2020 | 73 | 2020 |
| North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies UA Shah, EY Chung, O Giricz, K Pradhan, K Kataoka, S Gordon-Mitchell, ... Blood, The Journal of the American Society of Hematology 132 (14), 1507-1518, 2018 | 73 | 2018 |
| Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two … A Abbasi, S Peeke, N Shah, J Mustafa, F Khatun, A Lombardo, M Abreu, ... Journal of hematology & oncology 13, 1-4, 2020 | 69 | 2020 |
| T cell coinhibition and immunotherapy in human breast cancer M Janakiram, YM Abadi, JA Sparano, X Zang Discovery medicine 14 (77), 229, 2012 | 66 | 2012 |
| Whole-genome landscape of adult T-cell leukemia/lymphoma Y Kogure, T Kameda, J Koya, M Yoshimitsu, K Nosaka, J Yasunaga, ... Blood, The Journal of the American Society of Hematology 139 (7), 967-982, 2022 | 54 | 2022 |
| Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy M Zell, A Assal, O Derman, N Kornblum, R Battini, Y Wang, ... Oncotarget 7 (32), 51981, 2016 | 36 | 2016 |
